Volume 15, Number 4—April 2009
THEME ISSUE
The Amazon Region
Dispatches
Seroprevalence of Kaposi Sarcoma–associated Herpesvirus and Other Serologic Markers in the Brazilian Amazon
Table 2
Variables | aOR (95% CI) |
||
---|---|---|---|
Mapuera Amerindians, n = 339 | Mapuera non-Amerindians, n = 181 | Manaus blood donors, n = 1,133 | |
Sex | |||
Male | 1 | 1 | 1 |
Female | 1.2 (0.7–2.2) | 1.0 (0.5–2.1) | 1.3 (1.0–1.7) |
p value |
0.5 |
0.9 |
0.08 |
Age group, y | |||
0–9 | 0.1 (0.05–0.4) | 0.1 (0.04–0.3) | |
10–17 | 0.2 (0.07–0.4) | 0.3 (0.1–0.7) | |
18–34 | 0.5 (0.2–1.2) | 0.4 (0.1–0.9) | 0.9 (0.7–1.3) |
>35 | 1 | 1 | 1 |
p value |
<0.001 |
<0.001 |
0.6 |
HSV-2 | |||
Negative | 1 | 1 | 1 |
Positive | 0.3 (0.1–0.9) | 2.7 (1.2–6.5) | 1.3 (1.0–1.6) |
p value | 0.03 | 0.02 | 0.09 |
*Seroreactivity by any serologic assay (whole virus ELISA, IFA-LANA, or IFA-lytic) in multivariable analysis. KSHV, Kaposi sarcoma–associated herpesvirus; IFA-LANA, immunofluorescence assay that detected latent-associated nuclear antigens; IFA-lytic, IFA that detected lytic-associated nuclear antigens; aOR, age- and sex-adjusted odds ratio; CI, confidence interval; HSV-2, herpes simplex virus type-2.
Page created: December 10, 2010
Page updated: December 10, 2010
Page reviewed: December 10, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.